ADC Therapeutics Reports 89.8% ORR, 77.6% CR for ZYNLONTA Combo.

ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b trial of ZYNLONTA in combination with glofitamab for relapsed or refractory DLBCL. The combination demonstrated an 89.8% overall response rate and 77.6% complete response rate across 49 efficacy-evaluable patients with at least 6 months of follow-up. The safety profile was manageable, and the trial is on track to complete enrollment in 1H 2026. Data will be shared at a medical meeting and submitted for publication by end of 2026.